Advertisement

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
DOWNLOAD WHITEPAPER

End-to-End Process for Large-Scale Adenovirus Manufacturing

Recent advances in personalised regenerative medicine have been significant. However, further developments are needed to support market and regulatory demands, particularly the development of manufacturing processes to support large scale batches of high-quality viral vectors. Here, Pall Corporation describes the development of a robust integrated adenoviral manufacturing platform using adherent cells. A step-by-step scalable approach was implemented starting from laboratory scale to develop a fully integrated and reproducible process. Such a well-controlled operational manufacturing process allowed the production of large amounts of high-quality viral vector in compliance with good manufacturing practice (GMP) requirements suitable for the clinical trials.

Download to find out more.

Close
Close
Close

Go Top